Vivimed Labs Limited Share Price & Company Info
- Market cap
- ₹45.85 Cras reported by NSE
- 52-week high
- ₹29.4018-DEC-2025
- 52-week low
- ₹4.7511-AUG-2026
- Face value
- ₹2.00
- Shares issued
- 8,29,13,915
- Volume
- 14,753₹0.01 Cr traded
- Price band
- 2%₹5.53 – ₹5.75 on 2026-11-02
- Annual volatility
- 142.33%NSE, from daily returns
- Series
- BZtrade-for-trade
- BSE group
- Zscrip code 532660
- ISIN
- INE526G01021
- Listed on NSE
- 17-Aug-2005
About Vivimed Labs Limited
Vivimed Labs Limited is listed on the National Stock Exchange of India under the symbol VIVIMEDLAB in the BZ series. NSE classifies it under the basic industry Pharmaceuticals, part of the Healthcare sector. Its shares were listed on NSE on 17-Aug-2005. Each share has a face value of ₹2.00.
In the end-of-day data for 16 November 2026 the stock closed at ₹5.15, down 0.96% on the day. NSE puts the company's market capitalisation at about ₹45.85 crore, which puts it among the smallest listed companies in India. Over the past 52 weeks it has traded between ₹4.75 and ₹29.40, so the last price is 8.4% above the low and 82.5% below the high.
BZ is a trade-for-trade series for companies the exchange has flagged for not meeting listing requirements, for example late or missing filings. Every trade must be settled by delivery.
NSE currently lists a regulatory note for this stock: IBC-1 | Scrip is in BZ/SZ series | EPS based on prev. 4 trailing Qtrs. in the scrip is zero | Less than 100 unique PAN traded in prev. 30 days, meaning the company is under insolvency proceedings. Notes like these come from the exchange's surveillance and disclosure checks and can mean higher margins, trade-for-trade settlement or limits on trading. Check the NSE quote page for the current position before trading.
NSE puts the stock's annualised volatility at 142.33%. That is very high: moves of several percent in a single day are routine.
Because the share trades below ₹10, it also appears in our list of penny stocks under ₹10, which explains the extra risks that come with low-priced shares.
Vivimed Labs Limited quarterly results
In the quarter ended March 2026 (audited), Vivimed Labs Limited reported total income of ₹7.55 crore and a net loss of ₹141 crore, or ₹-17.14 per share.
A year earlier, in the March 2025 quarter, income was ₹26.73 crore with a net loss of ₹3.84 crore. Income has fallen 71.8% year on year.
Vivimed Labs Limited was profitable in 0 of the 4 quarters shown below, and made a loss in all of them. Figures are as filed with NSE, in ₹ crore.
| Quarter ended | Total income | Profit before tax | Net profit | EPS | Status |
|---|---|---|---|---|---|
| March 2026 | 7.55 | -141 | -141 | -17.14 | Audited |
| September 2025 | 18.82 | -7.44 | -7.44 | -0.90 | Un-Audited |
| June 2025 | 18.30 | -5.49 | -5.49 | -0.66 | Un-Audited |
| March 2025 | 26.73 | -3.84 | -3.84 | -0.60 | Audited |
Vivimed Labs Limited shareholding pattern
At the end of March 2026, promoters and the promoter group held 7.57% of Vivimed Labs Limited, with the public holding 92.43%. That is down 13.37 percentage points from 20.94% in June 2024.
A promoter stake below 25% is low by Indian standards. It can mean ownership is widely spread, or that the founders have sold down over time, so it is worth reading the annual report to see who controls the company.
A falling promoter stake is one of the things investors watch most closely in small companies, because it can signal insiders selling. The quarterly shareholding filings on NSE show who bought or sold.
| Quarter ended | Promoter & Promoter Group (%) | Public (%) |
|---|---|---|
| March 2026 | 7.57 | 92.43 |
| December 2025 | 7.77 | 92.23 |
| September 2025 | 7.77 | 92.23 |
| June 2025 | 7.77 | 92.23 |
| March 2025 | 20.94 | 79.06 |
| December 2024 | 20.94 | 79.06 |
| September 2024 | 20.94 | 79.06 |
| June 2024 | 20.94 | 79.06 |
Vivimed Labs Limited share price performance
Over the past year the Vivimed Labs Limited share price has gained 0.00%, against a fall of 10.92% for the NIFTY 50, so it has outperformed that index by 10.92 percentage points.
Across the 5 periods in the table, the stock beat the NIFTY 50 in 2. Past returns describe what happened; they do not predict what comes next.
| Period | VIVIMEDLAB | NIFTY 50 |
|---|---|---|
| 1 month | +1.65% | +1.91% |
| 3 months | +7.59% | -5.20% |
| 6 months | -18.44% | -3.94% |
| 1 year | 0.00% | -10.92% |
| 5 years | -70.97% | +30.45% |
Vivimed Labs Limited vs industry peers
NSE compares Vivimed Labs Limited with 6 other listed companies in Pharmaceuticals. By market capitalisation it ranks 4 of 7.
| Company | Market cap | Price (₹) | P/E | Promoter % | Qtr income | Qtr net profit |
|---|---|---|---|---|---|---|
| ZENITHDRUG | 63.45 | 37.00 | 16.09 | 69.98 | 96.18 | 1.61 |
| SUNLOC | 63.12 | 61.55 | — | 0.00 | — | — |
| BIOFILCHEM | 47.18 | 28.99 | 96.41 | 46.79 | 7.67 | 0.21 |
| VIVIMEDLAB | 45.85 | 5.53 | — | 7.57 | 7.55 | -141 |
| MANGALAM | 45.25 | 28.59 | — | 35.65 | 67.38 | -13.06 |
| NATCO-RE | 44.27 | 25.95 | — | 0.00 | — | — |
| MEDIORG | 39.43 | 26.50 | — | 59.73 | 4.61 | -4.98 |
Vivimed Labs Limited announcements, board meetings and corporate actions
Latest announcements
The most recent filings Vivimed Labs Limited has made with NSE, newest first:
- 22-Oct-2026 · Clarification - Financial Results: The Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Impact of Audit Qualifications in case of modified opinion(s) The response of the Company is awaited.
- 15-Oct-2026 · Outcome of Board Meeting: Vivimed Labs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. (PDF)
- 28-Sep-2026 · Updates: Vivimed Labs Limited has informed the Exchange regarding 'COC meeting'. (PDF)
- 26-Sep-2026 · General Updates: Vivimed Labs Limited has informed the Exchange about General Updates (PDF)
- 23-Sep-2026 · Trading Window: Vivimed Labs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 (PDF)
- 08-Sep-2026 · Corporate Insolvency Resolution Process: Vivimed Labs Limited has informed the Exchange about Corporate Insolvency Resolution Process (PDF)
- 17-Aug-2026 · Corporate Insolvency Resolution Process: Vivimed Labs Limited has informed the Exchange about Corporate Insolvency Resolution Process (PDF)
- 31-Jul-2026 · Clarification - Financial Results: The Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.
Board meetings
- 17-Jul-2026 · Financial Results: To consider and approve the financial results for the period ended March 31, 2026
- 30-May-2026 · Financial Results: VIVIMEDLAB : 30-May-2026 : The Company has informed the Exchange that a Board meeting to be held on May 28, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 30, 2026, To consider and approve the financial results for the period ended March 31, 2026
- 30-May-2026 · Board meeting Rescheduled: Vivimed Labs Limited has informed the Exchange that the meeting of the Board of Directors of the Company scheduled to be held on May 30, 2026 has been postponed
- 28-May-2026 · Financial Results: To consider and approve the financial results for the period ended March 31, 2026
- 13-Mar-2026 · Financial Results: To consider and approve the financial results for the period ended December 31, 2025
Corporate actions
The corporate actions on record include 2 dividends, 1 share split. The ex-date is the first day the shares trade without the entitlement.
- Annual General Meeting · ex-date 27-Dec-2024 · book closure 28-Dec-2024 to 03-Jan-2025
- Annual General Meeting · ex-date 07-Nov-2023 · book closure 08-Nov-2023 to 13-Nov-2023
- Annual General Meeting · ex-date 21-Mar-2023 · book closure 22-Mar-2023 to 27-Mar-2023
- Annual General Meeting · ex-date 10-Feb-2023 · book closure 13-Feb-2023 to 17-Feb-2023
- Annual General Meeting · ex-date 23-Dec-2020 · book closure 25-Dec-2020 to 30-Dec-2020
- Annual General Meeting · ex-date 23-Sep-2019 · book closure 25-Sep-2019 to 30-Sep-2019
- Annual General Meeting/Dividend Re 0.40 Per Share · ex-date 19-Sep-2018 · book closure 22-Sep-2018 to 27-Sep-2018
- Annual General Meeting/Dividend - Re 0.40 Per Share · ex-date 21-Sep-2017 · book closure 23-Sep-2017 to 29-Sep-2017
- Annual General Meeting · ex-date 22-Sep-2016 · book closure 26-Sep-2016 to 30-Sep-2016
- Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share · ex-date 06-Apr-2016 · record date 08-Apr-2016
Risk notice: low-priced and small-company shares can be illiquid, volatile and subject to manipulation, and shareholders can lose their entire investment. This page is a factual summary, not a recommendation to buy or sell Vivimed Labs Limited.
Where to find Vivimed Labs Limited's financials
Direct downloads from NSE:
- Annual report 2024-25 (PDF, 2.11 MB)
- Annual report 2023-24 (PDF)
- Annual report 2022-23 (ZIP)
- Annual report 2021-22 (ZIP)
- Annual report 2020-21 (ZIP)
- Annual report 2019-20 (ZIP)
For full financial statements, shareholding detail and every company announcement, go to the source:
- NSE quote pageOfficial price, price band, surveillance status, shareholding pattern and corporate actions.
- Annual reports (NSE)Search “VIVIMEDLAB” to download Vivimed Labs Limited's annual reports as filed with the exchange.
- Announcements and results (NSE)Search “VIVIMEDLAB” for quarterly results, board meetings and other company filings.
- BSE quote page (532660)BSE price, filings, results and shareholding for the same company.
- ScreenerTen years of profit and loss, balance sheet, cash flow and key ratios.
- TradingView chartInteractive price chart with technical indicators.
- Google FinanceQuick price overview and recent news coverage.
- Yahoo FinanceHistorical prices you can download, plus summary statistics.
Other Pharmaceuticals stocks on MCX Trends
- Syncom Formulations (India) Limited (SYNCOMF · ₹21.19)
- Anlon Healthcare Limited (AHCL · ₹25.77)
- Sigachi Industries Limited (SIGACHI · ₹28.16)
- Vineet Laboratories Limited (VINEETLAB · ₹37.52)
- Ambalal Sarabhai Enterprises Limited (AMBALALSA · ₹38.62)
- Medico Remedies Limited (MEDICO · ₹18.31)
- Nectar Lifesciences Limited (NECLIFE · ₹10.31)
- Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM · ₹30.67)
Frequently asked questions
What is the Vivimed Labs Limited share price?
Vivimed Labs Limited (NSE: VIVIMEDLAB) closed at ₹5.15 in the end-of-day data for 16 November 2026. For a live price, use the NSE quote page or your broker, because this page is updated from end-of-day files.
Which sector does Vivimed Labs Limited belong to?
NSE classifies Vivimed Labs Limited under Pharmaceuticals, in the Healthcare sector.
What is the 52-week high and low of VIVIMEDLAB?
The 52-week high is ₹29.40 (18-DEC-2025) and the 52-week low is ₹4.75 (11-AUG-2026), according to NSE.
Is Vivimed Labs Limited a penny stock?
At ₹5.15 the share trades below ₹10, so it appears on our list of penny stocks under ₹10. A low share price on its own says nothing about whether a company is cheap or expensive; market capitalisation, debt, profits and exchange surveillance status matter far more.
What is the promoter holding in Vivimed Labs Limited?
Promoters and the promoter group held 7.57% of Vivimed Labs Limited at the end of March 2026, according to the shareholding pattern filed with NSE.
What were Vivimed Labs Limited's latest quarterly results?
For the quarter ended March 2026, Vivimed Labs Limited reported total income of ₹7.55 crore and a net loss of ₹141 crore (EPS ₹-17.14).
Where can I find Vivimed Labs Limited's annual report and financial results?
Annual reports, quarterly results and other filings are published on the NSE corporate filings pages (search for VIVIMEDLAB) and on BSE. Screener also lays out several years of financial statements in one place. Links to all of these are above.